- Home
- IMRN vs IMNN Comparison
IMRN vs IMNN Comparison
Compare IMRN & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- IMNN
- Stock Information
- Founded
- IMRN 1994
- IMNN 1982
- Country
- IMRN Australia
- IMNN United States
- Employees
- IMRN N/A
- IMNN N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- IMNN Health Care
- Exchange
- IMRN Nasdaq
- IMNN Nasdaq
- Market Cap
- IMRN 9.2M
- IMNN 12.1M
- IPO Year
- IMRN N/A
- IMNN 1985
- Fundamental
- Price
- IMRN $1.74
- IMNN $0.72
- Analyst Decision
- IMRN Strong Buy
- IMNN Buy
- Analyst Count
- IMRN 1
- IMNN 2
- Target Price
- IMRN $5.00
- IMNN $14.00
- AVG Volume (30 Days)
- IMRN 23.5K
- IMNN 2.0M
- Earning Date
- IMRN 07-15-2025
- IMNN 08-13-2025
- Dividend Yield
- IMRN N/A
- IMNN N/A
- EPS Growth
- IMRN N/A
- IMNN N/A
- EPS
- IMRN N/A
- IMNN N/A
- Revenue
- IMRN $4,048,286.00
- IMNN N/A
- Revenue This Year
- IMRN N/A
- IMNN N/A
- Revenue Next Year
- IMRN N/A
- IMNN N/A
- P/E Ratio
- IMRN N/A
- IMNN N/A
- Revenue Growth
- IMRN 82.90
- IMNN N/A
- 52 Week Low
- IMRN $1.50
- IMNN $0.37
- 52 Week High
- IMRN $2.87
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- IMRN 48.56
- IMNN 38.94
- Support Level
- IMRN $1.67
- IMNN $0.70
- Resistance Level
- IMRN $1.78
- IMNN $0.86
- Average True Range (ATR)
- IMRN 0.10
- IMNN 0.07
- MACD
- IMRN -0.01
- IMNN -0.03
- Stochastic Oscillator
- IMRN 49.97
- IMNN 5.94
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).